Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

An In-Home Study of Facioscapulohumeral Muscular Dystrophy (FSHD) Patients using Contactless Wireless Sensing and Machine Learning
Neuromuscular and Clinical Neurophysiology (EMG)
P10 - Poster Session 10 (5:30 PM-6:30 PM)
1-013

Assess the feasibility of measuring FSHD progression using Emerald, a contactless wireless sensor and machine learning platform for deep phenotyping of movement disorders.

FSHD is a rare, slowly progressive myopathy characterized by weakness initially in facial, shoulder, and upper limb muscles followed by abdominal and paraspinal weakness, and finally lower extremity weakness. FSHD affects between 16,000-38,000 people in the US, and its symptoms often progress over decades, creating significant challenges in tracking disease progression using in-clinic scales and functional tests.

Emerald is an emerging, contactless radio-wave based home monitoring system that measures gait speed, time in bed, sleep stages, and vital signs.  The device infers patient physiological signals by analyzing surrounding wireless signals using machine learning. Emerald has been validated in other neuromuscular populations including Parkinson’s Disease and is validated for the first time in FSHD.

12 FSHD patients were observed in their homes 24/7 for 3 months, using two Emerald devices per home, one each in the bedroom and living room. Patient disease severity ranged from mild to severe (Clinical severity score, CSS 1-4). Devices collected over 40,000 movement episodes, which were processed to extract gait speed and time to exit the bed. These metrics were correlated with CSS and Timed-Up-and-Go (TUG) measures collected at baseline.

Preliminary analysis shows a strong relationship between in-home gait speed and CSS. Initial investigation suggests evidence of a relationship between the time to exit bed and CSS with significant precision and accuracy relative to existing clinical metrics for FSHD.

Our results suggest that key FSHD progression traits can be sensitively tracked using continuous patient monitoring in the home setting. Emerald’s ability to sit in the background, and measure continuously in a touchless manner enables long duration studies with low overhead, which is valuable in a small patient population that requires extended observation.

Authors/Disclosures

PRESENTER
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Maya N. Hatch, PhD (UC Irvine School of Medicine) Maya Hatch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bioniks. Maya Hatch has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Fulcrum. The institution of Maya Hatch has received research support from Fulcrum Therapeutics.
Jay Han, MD (University of California Davis) No disclosure on file
Diego Cadavid, MD, FÂé¶¹´«Ã½Ó³»­ (Verge Genomics) Dr. Cadavid has received personal compensation for serving as an employee of Verge Genomics. Dr. Cadavid has received personal compensation for serving as an employee of Vertex Pharmaceuticals. Dr. Cadavid has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novo Nordisk. Dr. Cadavid has or had stock in Verge Genomics.Dr. Cadavid has or had stock in Vertex Pharmaceuticals.
No disclosure on file
No disclosure on file